Gnosis has over 20 years of experience in microbial fermentation for both oral- and injectable-grade, microbial-derived biopharmaceuticals.
Today, we are a leading manufacturer of active and functional ingredients for the nutrition, cosmetic, personal care, industrial biotech and pharmaceutical industries.
With our proprietary technology and sophisticated know-how, we have developed an unparalleled track record in delivering a broad array of high-quality products to our customers.
Gnosis was founded by a group of technicians and scientists to provide a reliable source of scientific and technological services in Cairate, near Varese. The laboratory had 6 employees.
1990 First Patent Application
The initial area of interest was the agricultural industry. An innovative process for the waste treatment by using the activity of microorganisms was developed.
1997 Industrial Manufacturing
A new management team joins the Company and the focus is now on pharmaceuticals. The large scale manufacturing of Active Pharmaceutical Ingredients starts by using outsourcing partners for the industrial production of active compounds derived from fermentation processes.
2003 R&D site
Gnosis decides to expand the R&D lab through the construction of the R&D centre in Desio (Milan). Gnosis was one of the first companies to be located in the PTB (Polo Tecnologico Brianza), a new technological park North East of Milan.
2004 Acquisition of the first Manufacturing unit
One year later Gnosis acquired from Abbott the Sant'Antonino manufacturing site (formerly known as Abbott Knoll Bioresearch). After two months from the acquisition the start-up of the plant was completed with the beginning of the production for nutrition ingredients.
2005 cGMP Certification
The production facility was licensed by Swissmedic in July 2005 for non sterile API's manufacturing. The GMP certificate was released, upon inspection, by the same Regulatory Authority in November 2005.
2006 Diversification production Capability
New manufacturing areas were built and qualified to introduce new technologies and to increase the range of products manufactured in Sant'Antonino.
2007 Kosher Certification
In November 2007 the Sant'Antonino plant was licensed with Kosher certification.
2008 S. boulardii
The increasing production capacity of S.boulardii allowed us to become leaders in the manufacturing of this pharmaceutical ingredient. Gnosis initiates a development program for probiotics.
2009 "Always Looking Ahead" Plan
After 20 years from the foundation Gnosis develops a Strategic Plan focusing on the core expertise of the biofermentation technology leading to 3 main areas of research:
• Probiotic strains
• API from biofermentation
• Alternative source
2009 Acquisition of BiMA
In order to support our mission, through the expansion of our manufacturing capabilities, Gnosis acquired the Pisticci Site from Pfizer on December, 1st 2009.
2011 Gnosis USA Inc.
Gnosis has selected Doylestown, Pennsylvania, as the home of its North America Branch Office, and formed a new entity, Gnosis USA Inc., that is expected to implement Gnosis strategic plans in United States and Canada.
2012 Expansion in Italy
Gnosis has expanded and updated its Headquarters in Italy. The building has been extensively renovated and designed to house multiple research departments for identification and development of new active ingredients.
2012 Gnosis China
In order to strengthen its business position in Asia-Pacific markets Gnosis has established Branch Office in Shanghai, China's leading industrial, commercial and financial center, the business springboard to expand overseas.
GNOSIS S.P.A. Sede Legale: Piazza del Carmine, 4 20121 Milano. P. IVA 02484720129 C. F. 10197170151 Cap. Soc. 3.000.000,00 € i.v. Registro delle imprese di Milano N° 10197170151